Jeffrey R. Balser
Known title: DirectorCIK: 0001751633
Associated companies
Transaction History
| CVS | ▲ Buy | Grant | 2,058 | $200K | 5/14/2026 | View on chart |
| CVS | ▲ Buy | Grant | 1,775 | $135K | 11/20/2025 | View on chart |
| CVS | ▲ Buy | Grant | 2,232 | $135K | 5/15/2025 | View on chart |
| CVS | ▲ Buy | Grant | 2,375 | $136K | 11/21/2024 | View on chart |
| CVS | ▲ Buy | Grant | 2,184 | $126K | 5/16/2024 | View on chart |
| CVS | ▲ Buy | Grant | 1,817 | $126K | 11/15/2023 | View on chart |
| CVS | ▲ Buy | Grant | 1,329 | $92K | 5/18/2023 | View on chart |
| CVS | ▲ Buy | Grant | 1,323 | $126K | 11/17/2022 | View on chart |
| CVS | ▲ Buy | Grant | 406 | $0 | 9/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status
CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.